Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Comparison of Adherence Between Nilotinib and Dasatinib As Second-Line Therapies in Chronic Myeloid Leukemia

Annie Guerin, MSc, Vamsi K Bollu, PhD, MBA, Amy Guo, PhD, Michael Stepner, BA, James D Griffin, MD, Eric Qiong Wu, PhD

Blood (2011) 118 (21): 2754.

https://doi.org/10.1182/blood.V118.21.2754.2754

Published: 2011

Journal Articles

Predictors of Treatment Non-Adherence in Patients Treated with Imatinib Mesylate for Chronic Myeloid Leukemia.

Meaghan StCharles, PhD, Vamsi K Bollu, PhD, MBA, Elizabeth Hornyak, BA, John Coombs, PharmD, MBA, Christopher M Blanchette, PhD, Daniel J. DeAngelo, MD, PhD

Blood (2009) 114 (22): 2209.

https://doi.org/10.1182/blood.V114.22.2209.2209

Published: 2009

Journal Articles

Non-Adherence to Imatinib in Chronic Myeloid Leukemia Patients Is Associated with a Short Term and Long Term Negative Impact On Healthcare Utilization and Costs.

Eric Qiong Wu, PhD, Vamsi K Bollu, PhD, MBA, Amy Guo, PhD, Annie Guerin, MSc, Andrew Peng Yu, PhD, Andres Sirulnik, MD, PhD, James D Griffin, MD

Blood (2009) 114 (22): 4270.

https://doi.org/10.1182/blood.V114.22.4270.4270

Published: 2009

Journal Articles

Lower Healthcare Resource Utilization Associated with Managing Nilotinib Related Adverse Events in Chronic Myeloid Leukemia (CML) Patients – Evidence From a Clinical Practice Setting Study.

Annie Guerin, MSc, Vamsi K Bollu, PhD, MBA, Denise Williams, MD

Blood (2009) 114 (22): 4285.

https://doi.org/10.1182/blood.V114.22.4285.4285

Published: 2009

Journal Articles

Comparison of Healthcare Utilization and Costs Between Nilotinib and Dasatinib as Second Line Therapies in Chronic Myeloid Leukemia.

Eric Qiong Wu, PhD, Vamsi K Bollu, PhD, MBA, Amy Guo, PhD, Annie Guerin, MSc, Magda Tsaneva, BA, Denise Williams, MD, James D Griffin, MD

Blood (2009) 114 (22): 4286.

https://doi.org/10.1182/blood.V114.22.4286.4286

Published: 2009

NARROW

Comparison of Adherence Between Nilotinib and Dasatinib As Second-Line Therapies in Chronic Myeloid Leukemia

Predictors of Treatment Non-Adherence in Patients Treated with Imatinib Mesylate for Chronic Myeloid Leukemia.

Non-Adherence to Imatinib in Chronic Myeloid Leukemia Patients Is Associated with a Short Term and Long Term Negative Impact On Healthcare Utilization and Costs.

Lower Healthcare Resource Utilization Associated with Managing Nilotinib Related Adverse Events in Chronic Myeloid Leukemia (CML) Patients – Evidence From a Clinical Practice Setting Study.

Comparison of Healthcare Utilization and Costs Between Nilotinib and Dasatinib as Second Line Therapies in Chronic Myeloid Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Comparison of Adherence Between Nilotinib and Dasatinib As Second-Line Therapies in Chronic Myeloid Leukemia

Predictors of Treatment Non-Adherence in Patients Treated with Imatinib Mesylate for Chronic Myeloid Leukemia.

Non-Adherence to Imatinib in Chronic Myeloid Leukemia Patients Is Associated with a Short Term and Long Term Negative Impact On Healthcare Utilization and Costs.

Lower Healthcare Resource Utilization Associated with Managing Nilotinib Related Adverse Events in Chronic Myeloid Leukemia (CML) Patients – Evidence From a Clinical Practice Setting Study.

Comparison of Healthcare Utilization and Costs Between Nilotinib and Dasatinib as Second Line Therapies in Chronic Myeloid Leukemia.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only